Picture of ABPRO Holdings logo

ABP ABPRO Holdings Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareMicro Cap

Momentum

Relative Strength (%)
1m-20.47%
3m-73.18%
6m-97%
1yr-97.27%
Volume Change (%)
10d/3m-55.27%
Price vs... (%)
52w High-97.55%
50d MA-35.35%
200d MA-94.37%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-85.1%
Return on Equity-92.66%
Operating Margin-561.43%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 201831st Dec 2019
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2018 / 2019

Blurred out image of ABPRO Holdings EPS forecast chart

Profile Summary

Abpro Holdings, Inc. is a biotechnology company dedicated to developing next-generation antibody therapeutics, which helps in improving the lives of patients with severe and life-threatening diseases. The Company is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its DiversImmune and MultiMab antibody discovery and engineering platforms, it is engaged in developing a pipeline of antibodies, both independently and through collaborations with global pharmaceutical and research institutions. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting human epidermal growth factor receptor 2 (HER2), and cluster of differentiation 3 (CD3), T-cell co-receptor.

Directors

    Last Annual
    December 31st, 2017
    Last Interim
    January 1st, 1970
    Incorporated
    May 20th, 2021
    Public Since
    January 14th, 2022
    No. of Employees
    6
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    us flag iconNASDAQ Global Market
    Shares in Issue
    52,219,378

    ABP Share Price Performance

    Similar to ABP

    Picture of 89bio logo

    89bio

    us flag iconNASDAQ Global Market

    Picture of Abivax SA logo

    Abivax SA

    us flag iconNASDAQ Global Market

    Picture of AC Immune SA logo

    AC Immune SA

    us flag iconNASDAQ Global Market

    Picture of Acrivon Therapeutics logo

    Acrivon Therapeutics

    us flag iconNASDAQ Global Market

    Picture of Actuate Therapeutics logo

    Actuate Therapeutics

    us flag iconNASDAQ Global Market

    FAQ